AstraZeneca shares drop sharply after the company reports results from a late-stage trial of a heart drug that did not meet its main efficacy goal. CNBC reports the stock falls by about 9% following the announcement. According to the report, AstraZeneca says the trial misses the primary endpoint, which is the trial’s main measure of whether the treatment produces the intended clinical benefit. Seeking Alpha also describes the decline in the context of the missed primary efficacy target, reinforcing that the trial outcome drives the market reaction. The sources focus on the company’s disclosure of the trial results and the immediate impact on AstraZeneca’s share price, rather than providing detailed numbers on how far the results missed the endpoint, specific endpoints assessed, or any follow-up plans. The reports therefore converge on the central point: the late-stage study does not achieve its primary goal, prompting an investor selloff reflected in the stock’s sharp decline.